Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Depreciation and Depletion (2016 - 2020)

Champions Oncology has reported Depreciation and Depletion over the past 11 years, most recently at $254000.0 for Q4 2020.

  • Quarterly results put Depreciation and Depletion at $254000.0 for Q4 2020, up 56.79% from a year ago — trailing twelve months through Oct 2020 was $295000.0 (up 49.75% YoY), and the annual figure for FY2025 was $150000.0, up 2.74%.
  • Depreciation and Depletion for Q4 2020 was $254000.0 at Champions Oncology, up from $224000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for CSBR hit a ceiling of $254000.0 in Q4 2020 and a floor of -$367000.0 in Q2 2020.
  • Median Depreciation and Depletion over the past 5 years was $98000.0 (2018), compared with a mean of $63117.6.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 208.33% in 2018 and later plummeted 54.85% in 2020.
  • Champions Oncology's Depreciation and Depletion stood at $34000.0 in 2016, then skyrocketed by 144.12% to $83000.0 in 2017, then skyrocketed by 38.55% to $115000.0 in 2018, then soared by 40.87% to $162000.0 in 2019, then skyrocketed by 56.79% to $254000.0 in 2020.
  • The last three reported values for Depreciation and Depletion were $254000.0 (Q4 2020), $224000.0 (Q3 2020), and -$367000.0 (Q2 2020) per Business Quant data.